Salah-Eddin Al-Batran, Prof. Dr. med.

Institut für Klinische Krebsforschung IKF GmbH · Institut für Klinische Krebsforschung am Krankenhaus Nordwest

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Salah-Eddin Al-Batran, Prof. Dr. med. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:58 UTC. Open this list on ClinicalTrials.gov

Ph2
NCT06981325 · Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Basal Cell Carcinoma (BCC), First Line Treatment · study director
N/A
NCT06050434 · Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · terminated · Soft Tissue Sarcoma · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.